IPR Page 1/8
`
`Santen/Asahi Glass Exhibit 2024
`Micro Labs v. Santen Pharm. and Asahi Glass
`IPR2017-01434
`
`

`

`Volume 4 number 7 1985
`
`Current
`Eye
`ReseaIch
`
`fl
`
`Pharmacological testing in the laser-induced monkey glaucoma model
`_____u_‘_______________________________________________.___.___________________._____________._________
`
`Ping-Yu Lee, Steven M. Podos, Julia R. Howard-Williams, Colette H. Severin. Aron D. Rose and Marc
`J. Siegel
`_____________________________.__________._._____________________________________.________________._.__.
`
`Department of Ophthalmology. Mount Sinai School of Medicine of the City University of New York.
`NY MID9,USA
`—..___.—.—-—-—-—-—————-————-—--—'——“——'—'
`
`Received on 26 March 1985; accepted on I] June 1985
`
`M A
`
`BSTRACT
`Glaucoma was induced in cynomolgus monkeys by
`photocoagulating the trabecular meshwork with the
`argon laser. Repeat treatments were often
`necessary and wide intraocular pressure fluctua-
`tions were characteristic.
`Baseline intraocular pressure was measured
`with a calibrated oneumatonometer hourly for six
`hours.
`On a succeeding day a baseline measure-
`ment was made, 50 pl of the drug to be tested
`applied, and six hourly measurements of
`intraocular pressure repeated.
`The effects on
`intraocular pressure of timolol, epinephrine,
`pilocarpine, vanadate, prostaglandin on
`(PGon), forskolin, and corynanthine were
`(p <
`tested in at
`least eight eyes. Significant
`0.05) reductions of
`intraocular pressure were
`produced by 0.5% tinnlol,
`2% epinephrine,
`4%
`pilocarpine, 1% vanadate, 500 pg of PGFgo and
`1% forskolin.
`Five per cent corynanthine
`produced no significant lowering of
`intraocular
`pressure.
`Tonography revealed an increased outflow
`facility associated with the reduction of
`intraocular pre55ure 2 hours after the admin-
`istration of 4% pilocarpine.
`This glaucoma animal model may be useful
`investigating agents that
`lower intraocular
`pressure by a variety of mechanisms.
`
`in
`
`INTRODUCTION
`
`produced transient or prolonged elevations of
`intraocular pressure. Glaucoma has been produced
`in rabbits by the injection of 11 kaolin into the
`anterior chamber, and by encircling the globe
`with cotton threads or rubber bands (1,3).
`Kupfer (4), by inserting a polyethylene tubing
`into the angle of the anterior chamber of the
`rabbit eye, produced an elevated intraocular
`pressure within 24 hours which remained elevated
`for at
`least 3 months.
`Samis (5) and Kazdan (6)
`created glaucona in rabbits by blocking the angle
`of the anterior chamber with methyl cellulose.
`Hamasaki and Ellenman {7) found that injection of
`alpha-chymotrypsin directly into owl monkey eyes
`caused an elevation in intraocular pressure.
`This technique has also been used successfully in
`rhesus monkeys (8) and rabbits (9).
`Intraocular
`pressure elevations lasting from 2 to 42 days
`have been produced in squirrel and cynonolgus
`monkey eyes by anterior chamber injections of
`autologous, fixed red blood cells {10).
`Gaasterland and Kupfer
`(11) described a new
`method for the production of sustained, elevated
`intraocular pressure in the rhesus monkey by
`repeated, circumferential argon laser photocoagu-
`lation of the mid-trabecular meshwork. This
`
`The search for animals with different types of
`spontaneous glaucoma has revealed a few models in
`rabbits. dogs, chickens, and primates (1).
`The
`general disadvantage of most animal models, with
`the exception of primates,
`is that the irido—
`corneal angle anatomy is different
`from that of
`the human. Although all species seem to have a
`continuous endothelial
`lining of the aqueous
`outflow channels.
`there are major differences in
`the presence of pectinate ligaments,
`a limited
`years. Quigley and Hohman (12) treated the
`trabecular meshwork of cynonolgus monkey eyes
`ciliary body museulature, and a scleral venous
`plexus instead of Schlemm's canal
`(2).
`with the argon laser by a variety of protocols in
`an attempt
`to cause moderate, consistent
`Historically,
`investigators have tried to
`intraocular pressure elevation. This was
`create animal models of glaucoma since as early
`as 1870.
`Some methods have failed and others
`achieved most satisfactorily with deliveries of
`—__—__————u————————I—I—t-Ifl-——I—
`775
`
`intra-
`technique caused a sustained elevation of
`ocular pressure, reduction of outflow facility,
`and retinal
`and optic nerve changes similar to
`those seen in human chronic, open—angle glaucoma.
`This model has been available for studies for 11
`
`© lRL Press Limited, Oxford, England.
`
`IPR Page 2/8
`
`IPR Page 2/8
`
`

`

`Current
`Eye
`Research
`
`
`
`
`least
`0.5 to 1.0 seconds and a total energy of at
`50 joules.
`8y light and electron microscopy,
`the
`trabecular beams were blunted, and scattered
`
`The disc changes in
`synechiae were present.
`these experimental eyes have been similar to
`
`those previously described in human eyes with
`glaucoma (13,14).
`A satisfactory animal model has not been
`available for the investigation of the effect of
`a number of commonly used clinical and
`
`experimental drugs for the treatment of glaucoma.
`The experimental model of glaucoma in rabbit
`induced by the posterior chamber injection of
`alpha—chymotrypsin has been studied as to the
`effects of timolol, epinephrine, norepinephrine,
`isoproterenol and propranolol on intraocular
`pressure (15).
`The effect of tepical pilocarpine
`on intraocular pressure has been studied in
`
`we
`normotensive and glaucomatous beagles (16).
`carried out a study of the effect of topically
`
`applied timolol, epinephrine, pilocarpine,
`vanadate, prostaglandin F23, forskolin and
`corynanthine on intraocular pressure in the
`laser—induced monkey glaucoma model.
`
`MATERIALS AND METHODS
`
`Eight cynomolgus monkeys weighing 3 to 4 kg,
`were used. Baseline examination showed eyes with
`normal anterior chamber angles, nonnal
`intra-
`ocular pressure, normal Outflow facility. clear
`ocular media. and nonmal optic nerveheads.
`
`Following baseline examination, 13 eyes
`(bilateral
`in 5 monkeys and unilateral
`
`in 3
`
`meshwork for 360°.
`
`Fundus examinations and
`
`intraocular pressure measurements were repeated
`every seven days. Retreatment of the trabecular
`meshwork with laser was done if the intraocular
`
`the
`
`pressure remained normaL
`For the intraocular pressure measurements,
`monkeys were kept
`in a sitting position in
`specially designed chairs throughout each experi-
`ment.
`The intraOCular pressure was measured with
`a Model 30R pneumatonometer (Digilab, Inc.,
`Cambridge, Massachusetts, U.S.A.) in animals
`lightly anesthetized with ketamine hydrochloride,
`3-5 mg/kg given intramuscularly, about
`5 minutes
`before each measurement.
`The instrument was
`
`calibrated by the manufacturer for humans and the
`verifier was used to check the tonometer
`
`calibration. Topical 0.5% proparacaine
`anesthesia was instilled prior to all
`intraocular
`pressure measurements.
`
`The drugs employed included sodium chloride
`0.9%,
`timolol maleate 0.5% (Merck Sharp 8. Dohme,
`Hest Point, Pa., U.S.A.), L—epinephrine HCl
`2%
`(Alcon Laboratories, Inc., Fort Worth, Texas,
`U.S.A.), pilocarpine H01 4% (Alcon, Humacao,
`
`Puerto Rico, U.S.A.), prostaglandin Fag
`(PGFZu),
`5 mg/ml
`(The Upjohn Co., Kalamazoo,
`Michigan, U.S.A.), vanadate (NaV03)
`(E. Merck,
`Darmstadt, Germany) prepared as a 1% solution in
`distilled water,
`10% DMSO, and 5% Tween 80,
`forskolin (Calbiochem Behring 00., La Jolla,
`Calif., U.S.A.) prepared as a 1% suspension in
`isotonic buffered saline containing 0.5%
`methylcellulose, and corynanthine (Sigma 00., St.
`Louis, Mo., U.S.A.) prepared as a 5% solution in
`distilled water.
`The vanadate, forskolin, and
`corynanthine were prepared fresh daily prior to
`topical ocular delivery.
`We did not use vehicles
`in the control measurements for vanadate and
`forskolin because the vehicles had no effects on
`
`monkeys) were treated using the argon laser
`(Coherent Radiation Model 9900, U.S.A.).
`Ketamine hydrochloride was
`injected intra—
`muscularly (5-10 mg/kg) for sedation during laser
`therapy.
`The eyes were treated with topical
`proparacaine 0.5% and photocoagulated using a
`single mirror goniolens specially made to
`cynomolgus monkey specifications (Ocular
`Instruments, Bellevue, Washington, U.S.A.).
`One drop
`experiments a 50 pl drop size was used.
`Between 50 and 130 50-micron spots of 1000-1500
`(50 pl) was used of sodium chloride,
`timolol,
`mN power and 0.5 seconds exposure time were
`L-epinephrine, pilocarpine, vanadate, forskolin,
`applied to the mid-portion of the trabecular
`and corynanthine, and two drops were used of
`—'———————_———_—_—
`
`intraocular pressure in normal cynomolgus monkey
`eyes in our previous studies.
`For all
`
`776
`
`IPR Page 3/8
`
`IPR Page 3/8
`
`

`

`Currth
`Eye
`Research
`
`
`PGqu three to five minutes apart:
`The glaucomatous monkeys underwent baseline
`(control day) and drug treated (treated day)
`6-hour diurnal curves, the intraocular pressure
`being recorded at 9:30 a.m., 10 a.m., 10:30 a.m.,
`11:30 a.m., 12:30 p.m., 1:30 p.m., 2:30 p.m., and
`3:30 p.m.
`The baseline diurnal curve served as a
`control and was made 1 or 2 days before the
`experimental (treated) diurnal curve.
`0n the
`experimental day baseline intraocular pressure
`was measured at 9:30 a.m.
`Each drug was admin-
`istered to both eyes of the monkey immediately
`after the 9:30 a.m. measurement
`[0 hour).
`
`Included in this study were those monkey eyes in
`which the intraocular pressure was 22 mm Hg or
`more in both the baseline diurnal curve and the
`
`drug treated baseline intraocular pressure
`measurements.
`A two-week washout period was
`
`employed between testing each drug on the same
`monkey. Occasionally the same eye was used twice
`to test the same drug.
`
`Tonography was performed after using 4%
`pilocarpine with an EDT-103 tonography unit
`(Alcon). Baseline outflow facility was
`determined between 9 a.m. and 10 a.m., 2 hours
`before administration of 4% pilocarpine.
`
`Tonography was repeated 2 hours after drug
`administration. Outflow facility values were
`
`approximated from the 1955 Friedenwald tables.
`We employed two methods to analyze the changes
`intraocular pressure after drug administra-
`of
`tion, because of
`the wide intraocular pressure
`fluctuations in the glaucomatous monkey model-
`Method 1: The intraocular pressures on the
`
`treated day were compared to that on the control
`day. Method 2:
`The differences in intraocular
`pressures at
`intervals after therapy between the
`treated and control day measurenents were
`
`(0 hour) differences
`compared to the initial
`between the treated and control day values.
`
`RESULTS
`
`meshwork and caused immediate blanching. bubble
`formation, and pigment scatter. Occasionally,
`small hyphema was noted.
`The intraocular
`pressure often fell the week following treatment
`and rose on the subsequent week or fell
`if the
`
`a
`
`treatment had been inadequate. Three eyes
`maintained a raised intraocular pressure after
`only one treatment session of 55—72 joules but
`most eyes needed 2-5 treatment sessions. Hide
`pressure fluctuations were noted in all monkey
`eyes as previously reported by Pederson and
`
`Gaasterland (13). Optic disc cupping was
`ultimately noted in 8 out of the 13 eyes during
`the course of this study. All eyes showed fixed
`mydriasis which may be due to laser-induced
`damage of ciliary nerves that pass through the
`ciliary body and innervate the iris sphincter
`(13).
`The effects of sodium chloride,
`
`timolol,
`
`epinephrine, pilocarpine, vanadate, PGFQG,
`forskolin. and corynanthine on the intraocular
`pressure in this glaucomatous nnnkey model are
`shown in Table L
`
`Intraocular pressures before a single
`instillation of these drugs (0 hour) were similar
`in treated and control day measuranents in all
`
`Sodium chloride 0.9% instillations had
`groups.
`no significant effect on intraocular pressure,
`comparing control and drug treated 6-hour diurnal
`curves.
`
`The 0.5% timolol significantly (p < 0.05)
`lowered intraocular pressure from 3 to 6 hours
`after instillation.
`The maximum effect occurred
`
`5 hours after drug administration, and persisted
`at this level for an additional
`1 hour. at which
`time the experiments were terminated.
`Topical application of 2% epinephrine to the
`monkey eyes produced a significant (p < 0.05)
`decrease in intraocular pressure occurring
`between 0.5 and 6 hours after drug administra-
`tion.
`The maximum reduction in intraocular
`
`pressure. occurred 1 hour after drug applica-
`tion.
`
`Elevated intraocular pressure (10?) was
`achieved in all 13 eyes treated with the argon
`Four percent pilocarpine produced a
`laser. Treatment was to the mid—trabecular
`significant
`(p < 0.05) reduction of intraocular
`
`
`IPR Page 4/8
`
`777
`
`IPR Page 4/8
`
`

`

`Current
`Eye
`Research
`
`
`Table 1: Effect of Sodium Chloride, Timolol, Epinephrine, Pilocarpine, Vanadate, PGFga, Forskolin, and
`Corynanthine, Topically Administered, on the Intraocular Pressure in Glaucomatous Cynomolgus Monkey Eyes
`
`Eye
`No.
`
`12
`
`12
`
`8
`8
`
`8
`B
`
`Groups?
`
`Control
`Sodium
`chloride 0.9%
`
`Control
`Timolol, 0.5%
`
`Control
`Epinephrine,
`
`2%
`
`4%
`
`Mean intraocular pressure {mm Hg : S.E.)
`
`0 Hr1
`
`0.5 hr
`
`1 hr
`
`2 hrs
`
`3 hrs
`
`4 hrs
`
`5 hrs
`
`6 hrs
`
`36.013.4
`
`35.8:3.5
`
`35.4+3.4
`
`34.1:J.2
`
`35.51;.2
`
`35.013.0
`
`32.9:2.8
`
`33.?:3.3
`
`34.0:3.6
`
`33.7:3.8
`
`33.4:§.8
`
`33.5:3.8
`
`33.0:3.8
`
`32.9:fl.0
`
`33.1:§.2
`
`32.4:4.3
`
`35.9:4.4
`36.8:4.6
`
`38.313.3
`34.6:3.5
`
`34.11fi.4
`34.6:A.3
`
`3E.5:fl.4
`29.9:fi.4
`
`2&.9¢}.B
`25.4:3.7
`
`29.§;3.9
`22.9:4.1§
`
`29.3:3.8
`21.4:fi.5§
`
`27.8;3.9
`19.8:3.7§
`
`28.0:4.0
`20.9:3.7§
`
`39.5:3.5
`28.413.E§
`
`39.8:3.9
`39.513.8
`40.0:3.3
`23.8:fi.z§ 29.519.6§ 30.3:§.6§
`
`39.0:§.0
`29.315.8§
`
`38.0:4.3
`28.0:5.9§
`
`35.0:4.5
`26.3:§.6*
`
`33.63;.9
`23.3:§.3§
`
`32.?12.9
`24.2:§.2§
`
`31.9:3.1
`24.0:3.4*
`
`34.4:3.3
`25.4:§.2§
`
`34.1+2.9
`34.113.2
`23.1:3.3§ 23.523.2§
`
`33.6:§.0
`24.4:§.B§
`
`40.1:3.9
`36.313.8*
`
`42.1:3.4
`41.0+3.7
`37.6f3.9* 35.6:fi.4
`
`42.9:3.4
`34.3:4.7*
`
`42.51;.6
`34.3:fl.8
`
`Control
`Pilocarpine,
`
`Control
`Vanadate,
`
`1%
`
`Control
`PGon, 0.005%
`
`Control
`Forskolin,
`
`1%
`
`14
`14
`
`8
`8
`
`9
`9
`
`9
`9
`
`35.0+3.4
`33.7f3.2
`
`39.1:3.8
`37.3:4.1
`
`32.2+3.9
`32.732.8
`
`33.0:3.8
`33.6:3.2
`
`29.7:3.4
`32.1:3.0
`
`32.3:; 9
`29.1:4.0
`
`14
`Control
`Corynanthine,5% l4
`
`34.6:3.0
`32.1:3.1
`
`33.0:2.9
`31.1 3.2
`
`33.012.7
`29.3:3.5
`
`31.6:2.9
`29.3:3.6
`
`31.9:3.0
`29.1+3.7
`
`28.0:3.3
`28.413.5
`
`32.1:A.0
`27.110.7§
`
`30.4+3.8
`25.933.9§
`
`28.?3fi.1
`23.0:0.7§
`
`33.913.7
`31.913.6
`27.814.1§ 30.1:fi.4
`
`34.1:3.9
`30.0:9 3
`
`32.1:3.B
`29.4:9.4
`
`32.0+3.4
`30.5E3.8
`
`41.1:3.7
`34.6:4.4
`
`27 3+3 4
`24 {E3 6
`
`29.8:3.6
`29 Eifi 3
`
`32.913 5
`30.4+5 5
`
`39.4:3.?
`35.614.3
`
`26.4+3.0
`24.7E3.4
`
`28.?13.2
`28.7:4.5
`
`33.0:3.6
`31.0:4.1
`
`(sodium chloride, timolol, epinephrine,
`TBoth eyes of the drug—treated group were treated with 50 pl
`pilocarpine, vanadate,
`forskolin, and corynanthine) or 100 pl (PGde) of the indicated concentration.
`1Time after administration
`
`*Significantly different (p < 0.05) from the control day measurements at corresponding intervals, paired t—test.
`
`(p < 0.05) from the control day measurements at corresponding intervals and the
`QSignificantly different
`differences between the treated and control day measurements significantly different
`(p < 0.05) fran the initia
`(0 hr) differences between the treated and control day measurements, paired t-test.
`
`pressure at 0.5 to 6 hours after the drug
`administration.
`The maximum effect occurred at
`to 2 hours.
`One percent vanadate significantly (p < 0.05)
`decreased intraocular pressure in the treated
`eyes at 0.5, 1, and 3 hours only comparing
`control and treated day measurements.
`The
`
`l
`
`One percent forskolin significantly (p < 0.05)
`lowered intraocular pressure only at 1 hour after
`drug administration.
`There was no significant (p > 0.1) difference
`in intraocular pressure between treated and
`control eyes after 5% corynanthine
`administration.
`
`In 13 eyes of 8 glaucomatous monkeys, 2 hours
`maximum reduction occurred 3 hours after drug
`after a topical administration of 4% pilocarpine.
`administration.
`the mean intraocular pressure was significantly
`Topical application of 500 pg of PGon to
`(p < 0.001)
`reduced in the treated eyes as com-
`the monkey eyes PVDGUCEd a significant
`(P < 0-05)
`pared to the baseline value, and the mean outflow
`decrease in intraocular pressure occurring
`facility was significantly (p < 0.01) increased
`between 2 to 4 hours after drug administration.
`as conpared to the baseline value (Table 2).
`The levels of
`intraocular pressure reduction were
`similar at 2, 3, and 4 hours.
`Before laser photocoagulation,
`the intraocular
`
`
`778
`
`IPR Page 5/8
`
`IPR Page 5/8
`
`

`

`Current
`Eye
`Research
`
`
`The Effect of 4% Pilocarpine on the
`Table 2.
`Outflow Facility of 13 Eyes of 8 Glaucomatous
`Monkeys
`
`lntraocular
`
`pressure
`
`Outflow
`
`facility
`
`mean : S.E.
`mean : S.E.
`{El/min/mm Hg
`mm Hg)
`0.10 1 0.02
`35.? 1 3.1
`Baseline
`
`
`22.6 + 2.5*Treated 0.21 + 0.03T
`*Significantly different as conpared to baseline
`(p < 0.001), paired t«test.
`iSignificantly different as conpared to baseline
`(p < 0.01), paired t-test-
`
`pressure was 19.6 1 0.5 mm Hg (mean I S.E.) and
`the outflow facility was 0.57 1 0.05 pl/min/mm Hg
`in the 13 monkey glaucoma eyes.
`
`DISCUSSION
`
`The open anterior chamber angles and the optic
`nervehead changes in the monkey eyes with
`elevated intraocular pressure induced by laser
`treatment of the trabecular meshwork are similar
`
`to the findings in human eyes with open-angle
`glaucoma.
`The glaucomatous monkey model differs
`from human glaucoma by the presence of scattered
`anterior synechiae and wide intraocular pressure
`fluctuations.
`The weekly intraocular pressure
`fluctuation in the monkey glaucoma eyes (24 :»12
`
`mm Hg, mean IOP fluctuation_: 5.0.) is greater
`than in untreated human primary open-angle
`
`glaucoma. This finding is in agreement with that
`of previous workers (11,13).
`The mean maximum
`diurnal
`intraocular pressure fluctuation in the
`13 monkey glaucoma eyes is 8.1 mm Hg.
`Gaasterland and Kupfer (11) report that outflow
`facility, determined in laser-induced glaucoma of
`rhesus monkeys,
`ranges from 0.02 to 0.11
`pl/min/mm Hg
`(normal values: 0.33 to 0.75
`ul/min/mm Hg).
`The mean outflow facility is 0.10
`
`1 0.02 pl/min/mm Hg (mean :_S.E.) (normal values:
`0.57 i 0.05 pl/min/mm Hg)
`in our studies in 13
`cynomolgus glaucomatous monkey eyes.
`The two
`results are similar.
`
`in
`The present study employs drops of 50 pl
`order to mimic the clinical situation with regard
`to drop volume.
`Of note. a 50 pl drop is very
`large for the small monkey conjunctival cul de
`sec.
`
`The present experiments demonstrate that
`topical application of timolol, epinephrine,
`vanadate, PGFEo, pilocarpine, and forskolin
`significantly lower intraocular presSure in the
`laser-induced monkey glaucoma model and corynan-
`thine has no significant effect.
`The intraocular pressure lowering effects of
`timolol, epinephrine, and pilocarpine in this
`
`monkey model are consistent with their actions in
`clinical use.
`It is reaSSuring that the latter
`two compounds which act predominantly by
`increasing outflow facility are effective in the
`glaucomatous monkey eye since laser damage to the
`outflow mechanism must be rather extensive to
`
`In the present
`create the ocular hypertension.
`studyI the ocular hypotensive effect of
`pilocarpine is associated with an increase of
`Outflow facility measured tonographically.
`Vanadate, a potent inhibitor of the enzyme
`sodium-potassium-activated adenosine triphospha-
`
`lowers intraocular
`tase [(Na+, K*)ATPase],
`pressure in rabbits (17).
`The fall
`in
`intraocular pressure is not associated with
`significant changes in outflow facility or
`episcleral venous pressure. Topical
`administration of 1% vanadate in a formulation
`
`designed to enhance penetration reduces
`intraocular pressure in normal cynomolgus monkey
`
`eyes aSSOCTated with significant decreases in
`aqueous flow (18).
`The effects of this
`formulation of vanadate in the glaucoma monkey
`model are less impressive than those of the drugs
`in clinical use.
`
`Topical application of either prostaglandin
`
`PGEZ or PGFZo effectively reduces the
`intraocular pressure in rabbits. cats, and
`monkeys (19-21). Tonography reveals an increased
`facility of outflow but no change in aqueous flow
`simultaneous with the reduction of
`intraocular
`
`pressure in the normal eyes of cats and monkeys
`
`__———___—__—__——__
`
`779
`
`IPR Page 6/8
`
`IPR Page 6/8
`
`

`

`Current
`Eye
`Research
`
`
`the change in outflow facility does not
`As
`{22).
`account for the total observed reduction in
`
`intraocular pressure, other mechanisms may be
`possible which may or may not be operant
`in the
`glaucomatous monkEy model eye. Nevertheless, of
`the experimental drugs used in this study,
`PGon has the most significant effect on
`intraocular pressure.
`
`Forskolin is a unique activator of adenylate
`cyclase (23). Caprioli and Sears (24) report
`that topical ocular application of forskolin
`lowers intraocular pressure in rabbit, monkey,
`and humans and reduces aqueous flow in rabbit.
`In rabbits,
`intracameral
`injection of forskolin
`lowers intraocular pressure and increases outflow
`
`facility as measured by a constant pressure
`perfusion technique (25).
`A recent study (26)
`notes that
`topical administration of a 1%
`
`forskolin suspension significantly reduces
`intraocular pressure in normal cynomolgus monkey
`eyes associated with a signficant decrease in
`aqueous humor flow measured by a fluorophoto—
`metric technique and without change in
`tonographic outflow facility.
`The reductions of
`intraocular pressure induced in the present study
`are minimal.
`
`a selective ol—adrenergic
`Corynanthine,
`antagonist,
`is effective in the reduction of
`intraocular pressure when topically applied to
`the normal eyes of rabbits and monkeys (27).
`fall
`in intraocular pressure is not associated
`with significant changes in outflow facility 0r
`aqueous humor flow.
`The absence of an
`intraocular pressure effect
`in the glaucomatous
`monkey eye may reflect a severe reduction of
`the
`uve03cleral outflow mechanism induced by the
`laser procedure.
`
`The
`
`(1) suggests that the laser-induced
`Gelatt
`glaucoma monkey model will probably be most
`useful for the study of posterior segment changes
`as the extensive iridocorneal angle scarring
`will, for the most part, minimize many
`physiological and pharmacological alterations
`affecting aqueous outflow.
`The present study,
`however, demonstrates that the glaucoma monkey
`
`is not only suitable for investigating drug
`model
`that affect aqueous humor production (i.e.,
`timolol, vanadate, forskolin), but also suitable
`for investigating drugs that act on outflow
`
`(i.e., epinephrine. pilocarpine, PGFZG).
`Drawbacks of this glaucoma model are the wide
`intraocular pressure fluctuations and the
`
`instability of the model which limits long-term
`Experiments. Short-term pharmacological trials
`utilizing tonography and fluorophotometry are in
`prwrfis.
`
`ACKNDHLEDGEMENTS
`
`The authors would like to acknowledge
`Elizabeth Wilkins for assistance in preparation
`of the manuscript.
`This work was supported in part by grants
`EY03651 and EY01867 from the National Eye
`Institute, Bethesda, Maryland and by an
`unrestricted grant from Research to Prevent
`Blindness,
`Inc. Dr. Siegel was supported by a
`Mary and Alexander P. Hirsch award froh Fight for
`Sight, 1nc., N.Y., N.Y.
`
`EORRESPONDINB AUTHOR
`
`Steven M. Podos, M.D., Department of
`Ophthalmology, Mount Sinai School of Medicine of
`the City University of New York, One Gustave L.
`Levy Place, New York, N.Y.
`10029.
`
`REFERENCES
`(1977) Animal models for
`I. Gelatt, K.N.
`glaucoma.
`Invest. Ophthalmol. Vis. Sci. lg,
`592-596.
`(1971) Ultrastructure of the
`2. Tripathi, R.C.
`exit pathway of the aqueous in lower mammals.
`Exp. Eye Res. lg, 311-314.
`3. Kalvin, N.H., Hamasaki. and Gass, J.D.M.
`(1966) Experimental glaucona in monkeys.
`Arch. Ophthalmol. 19, 82-93”
`intraocular
`4. Kupfer, C.
`(1952) Studies of
`pressure: II. The histopathology of
`experimentally increased intraocular pressure
`in the rabbit.
`Invest. Ophthalnnl. I,
`474~479.
`F
`(1962)
`5. Semis. H.D.
`An experimental method to
`produce angle block in rabbits and the use of
`phospholine iodide after angle block.
`Am. J.
`Ophthalmol. 54, 1089—1091.
`6. Kazdan, J.Jf‘f1963) Experimental angle block
`avoiding paracentesis reflex.
`Am. J.
`Ophthalmol. §§, 836.
`
`———————————u———————n_n_—_______
`780
`
`IPR Page 7/8
`
`IPR Page 7/8
`
`

`

`Current
`Eye
`Research
`
`7.
`
`(1984)
`
`Lee, P., Podos, S.M.. and Severin, C.
`Effect of prostaglandin Fga on aqueous
`humor dynamics of rabbit, cat, and monkey.
`Invest. Ophthalmol. Vis. Sci. gs,
`1087-1093.
`(1981) Forskolin:
`Seamon. K.B. and Daly, J.N.
`a unique ditepene activator of cyclic AMP-
`gmmmthgsfitms. 1 Mcfic.le.Rn.7,
`201-224.
`_
`Caprioli, J. and Sears, M.
`(1983) Forskolin
`lowers intraocular pressure in rabbits,
`monkeys,
`and man.
`Lancet 1. 958-960.
`Bartels, S.P., Lee, 5.R., and Neufeld, A.H.
`(1982/1983) Forskolin stimulates cyclic AMP
`synthesis.
`lowers intraocular pressure and
`increases outflow facility in rabbits. Curr.
`Eye Res. 3, 673-681.
`Lee, P, Podos, S.M., Hittag, T., and
`Severin, C.
`(1984) Effect of topically
`applied forskolin on aqueous humor dynamics
`in cynomolgus nnnkey.
`Invest. Ophthalnol.
`Vis. Sci. 25, 1206-1209.
`Serle. J.E.. Stein, A.J., Podos, S.M.. and
`Severin, C.H.
`(1989) Corynanthine and
`aqueous humor dynamics in rabbits and
`
`monkeys. Arch. Ophthalmol. 102, 1385-1388.
`
`(1965)
`Hamasaki, 0.1. and Ellerman, N.
`Abolition of the electroretinogram following
`injection of a-chymotrypsin into the vitreous
`and anterior chamber of monkey. Arch.
`Ophthalmol. 73, 843-850.
`(1969)
`. Lessell, S. Efia Kuwabara, T.
`Experimental g—chymotrypsin glaucoma. Arch.
`Ophthalmol. 81, 353-854.
`Blood-aqueous
`(1974)
`. Sears. D. anEFSears, M.
`barrier and alpha-chymotrypsin glaucoma in
`rabbits.
`Am.
`J. Ophthalmol. 11, 378-383.
`Quigley, H.A.
`and Addicks, E.M.
`(1980)
`Chronic experimental glaucoma in primates:
`I]. Effect of extended intraocular pressure
`elevation on optic nerve head and axonal
`transport.
`Invest. Ophthalmol. Vis. Sci. 19,
`137-152.
`‘—
`(1974)
`Eaasterland, D. and Kupfer, C.
`Experimental glaucoma in the rhesus monkey.
`Invest. Ophthalmol. 13, 455-457.
`Quigley. H.A. and Hohman, R.M.
`(1983) Laser
`energy levels for trabecular meshwork damage
`in the primate eye.
`Invest. Ophthalmol. Vis.
`Sci. g5, 1305—1307.
`Pederson. J.E. and Gaasterland. D.E.
`Laser-induced primate glaucoma:
`I.
`Progression of cupping. Arch. Ophthalmol.
`102, 1689—1692.
`(1984)
`Radius, R.L. and Pederson, J.E.
`Laser—induced primate glaucoma: II.
`
`Histopathology. Arch. Ophthalmol. 102,
`1593-1698.
`Vareilles, P., Silverstone, 0., Plazonnet,
`3.. Douarec, J.-C.L., Sears, M.L., and Stone,
`C.A.
`(1977) Comparison of the effects of
`tinolol and other adrenergic agents on
`intraocular pressure in the rabbit.
`Invest.
`Ophthalmol. Vis. Sci. 1g, 987-995.
`Gwin, R.M., Gelatt, K.N., Gum, 6.6.,
`Peiffer, Jr., R.L., and Hilliams, L.N.
`The effect of topical pilocarpine on
`intraocular pressure and pupil size in the
`normotensive and glauconatous beagle.
`Invest. Ophthalmol. Vis. Sci. 1§J
`1143-1148.
`Krupin, T., Becker, B., and Podos, S.M.
`(1980) Topical vanadate lowers intraocular
`pressure in rabbits.
`Invest. Ophthalmol.
`Vis. Sci. 19, 1360-1363.
`Podos, S.M., Lee, P., Severin, C., and
`Mittag, T.
`(1984) The effect of vanadate on
`aqueous humor dynamics in cynomolgus monkeys.
`Invest. Ophthalmol Vis. Sci. 25, 359-361.
`Camras, 0.3., Bito, L.Z., and-Fakins, K.E.
`(1977) Reduction of intraocular pressure by
`prostaglandins applied topically to the eyes
`of conscious rabbits.
`Invest. Ophthalmol.
`Vis. Sci. lg, 1125—1134.
`(1982) Comparison
`Stern, F.A. and BitoI L.Z.
`of the hypotensive and other ocular effects
`of prostaglandins E2 and Fgo on cat and
`rhesus monkey eyes.
`Invest. Ophthalmol. Vis.
`Sci. 22, 588-598.
`(1981) Reduction
`Camras. 0.3. and Site, L.Z.
`of
`intraocular pressure in normal and
`glaucomtous primate (Aotus trivirgatus} eyes
`by topically applied prostaglandin Fag.
`Curr. Eye Res. 1, 205-209.
`
`781
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`(1984)
`
`(1977)
`
`10.
`
`1L
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`19.
`
`20.
`
`21.
`
`IPR Page 8/8
`
`IPR Page 8/8
`
`